Active Buzzers: Citigroup Inc, Boston Scientific Corporation, Morgan Stanley, Gilead Sciences
NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Citigroup Inc, Boston Scientific Corporation, Morgan Stanley, Gilead Sciences.
Citigroup Inc. (NYSE:C) stock declined 0.69% to $44.72. The company, on April 15, reported net income for the first quarter 2013 of $3.8 billion, or $1.23 per diluted share, on revenues of $20.5 billion. This compared to net income of $2.9 billion, or $0.95 per diluted share, on revenues of $19.4 billion for the first quarter 2012.
Is C Heading Towards New 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=C (OR Just copy and paste the link)
Additionally, the company on April 17 announces that it is inviting eligible holders (the "Noteholders") of its outstanding EUR1,250,000,000 4.25% Fixed Rate / Floating Rate Callable Subordinated Notes due February 2030 (the "2030 Notes") and EUR800,000,000 3.625% Fixed / Floating Rate Callable Subordinated Notes due November 2017 (the "2017 Notes", together with the 2030 Notes, the "Notes" and each a "Series") to tender their Notes for purchase by the Company for cash (each such invitation, an "Offer", and together, the "Offers").
Boston Scientific Corporation (NYSE:BSX) shares dropped 0.34% to $7.24. Morgan Stanley assumed coverage on shares of Boston Scientific in a report issued on April 16. The firm issued an overweight rating on the stock.
Is BSX a Buying Opportunity After The Recent Slump? Get Free Trend analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=BSX (OR Just copy and paste the link)
Moreover, on April 15, The first patient in the United States has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation ImageReady™ MR Conditional pacing system in the SAMURAI
clinical trial. The study is designed to confirm the safety and effectiveness of the system in the magnetic resonance imaging (MRI) environment.
Morgan Stanley (NYSE:MS) stock increased 0.05% to $20.59. The company on April 18 said its first-quarter profit increased to $984 million, or 50 cents a share, from a loss of $94 million or 6 cents per share in the first-quarter in 2012. Total revenue for the firm rose to $8.2 billion from $6.9 billion a year earlier. Earnings per share from continuing operations was 51 cents per share, compared with a loss of 5 cents a year earlier.
Adjusted earnings per share was 61 cents a share. Analysts expected the firm to report earnings of 57 cents a share on revenue of $8.35 billion.
Has MS Reached The Bottom and Ready To Hit New highs? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MS (OR Just copy and paste the link)
Gilead Sciences, Inc.(NASDAQ:GILD) shares climbed 1.01% to $53.71. Equities research analysts at Morgan Stanley boosted their price target on shares of Gilead Sciences from $46.00 to $65.00 in a research note issued to
investors on April 22.
Is GILD a Buy At New highs? Get Free Report Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=GILD (OR Just copy and paste the link)
Additionally, the company, on April 12, announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus (HCV) infection.
About bestdarnpennystocks.com
bestdarnpennystocks.com’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.
Disclaimer
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
bestdarnpennystocks.com
1419 Westwood Blvd Los Angeles, CA
90024-4911
staff@bestdarnpennystocks.com